Case report of durable responders to sintilimab plus second-line chemotherapy in relapsed/refractory angioimmunoblastic T-cell lymphoma.

Angioimmunoblastic T-cell lymphoma (AITL) is a highly aggressive lymphoma characterized by complex and unique clinicopathological and biological features, as well as a generally poor prognosis. First-line treatment typically consists of anthracycline-based chemotherapy regimens, yet the long-term outcomes remains unsatisfactory, with most patients eventually experiencing disease progression. For patients with relapsed/refractory (R/R) AITL, standard treatment options are limited, and enrollment in clinical trials is often prioritized in practice. Here, we report two cases of R/R AITL patients who received sintilimab combined with second-line chemotherapy after prior chemotherapy failure and achieved sustained disease remission. As of now, one patient had a progression-free survival (PFS) of nearly 2 years before succumbing to a non-tumor-related cause. The other patient continues to survive well, with a PFS of over 4 years. These cases suggest that the combination of immune checkpoint inhibitor and chemotherapy may represent a promising treatment option for selected R/R AITL patients, offering notable efficacy and controllable safety.